Johnson & Johnson JNJ

$267.14 -5.56 (-2.04%)

Valuation

Market cap
670,917,376,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
26.53
P/E (forward)
25.42
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,842,246
Avg volume
7,368,556
Day's range
$264.68 – $270.60
Shares out
2,407,310,000
Stochastic %K
29%
Beta
0.22
Analysts
Moderate Buy
Price target
$283.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Suite510 Nov 19, 11:49 PM
$JNJ $SPX Lawyers for shareholders say they are preparing for trial J&J estimated potential damages exceed $10 billion in Supreme Court filing. Lanier represented women who sued J&J over talc products ooops 😅
0 replies
Suite510 Nov 19, 11:47 PM
$JNJ $SPX oh look only 10 Billion out the window 🪟 😂
0 replies
Suite510 Nov 19, 11:39 PM
$JNJ $SPX More Xmas fun 🙈🎁 California Jury Awards $34.2 Million in Johnson & Johnson Talc Lawsuit Written by Tara Strand on November 19, 2026
0 replies
GridironGainz Nov 19, 9:36 PM 0 replies
GridironGainz Nov 19, 8:55 PM 0 replies
cuemark8 Nov 19, 8:46 PM
$JNJ About this time this overinflated stock tumbles. Take this back to 200 and I'll buy. I think just about every stock out there will test new 52 week lows soon .
0 replies
parcha Nov 19, 5:59 PM
https://www.cnbc.com/investingclub/2026/11/19/jim-cramers-top-10-things-to-watch-in-the-stock-market-thursday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $LLY $JNJ $ABBV $AMGN My power rankings of the drug stocks right now: Eli Lilly, Johnson & Johnson, AbbVie, and now Amgen. Amgen just got some love from Piper Sandler, which hiked its price target to $542 from $457 and kept its buy rating. Optimistic on an experimental treatment for the autoimmune condition Sjogren disease and the already approved lung cancer treatment Imdelltra. We own Lilly and J&J for the Club. This group has been working.
0 replies
peloswing Nov 19, 4:56 PM
$JNJ may be down over -2% today, but netflow is showing call selling NOT put buying! GEX Heatmap is showing the King Node at $270 for TOMORROW. $JNJ may see the supporting trendline and is likely to bounce, but even is that support level of ~$260 is broken, the 50WMA and VPoC is an additional level of support at $240-243!
0 replies